491 related articles for article (PubMed ID: 31725010)
1. Microbiome modulation to correct uremic toxins and to preserve kidney functions.
Caggiano G; Cosola C; Di Leo V; Gesualdo M; Gesualdo L
Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):49-56. PubMed ID: 31725010
[TBL] [Abstract][Full Text] [Related]
2. The Impact of CKD on Uremic Toxins and Gut Microbiota.
Rysz J; Franczyk B; Ławiński J; Olszewski R; Ciałkowska-Rysz A; Gluba-Brzózka A
Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33807343
[TBL] [Abstract][Full Text] [Related]
3. The clinical impact of gut microbiota in chronic kidney disease.
Kim SM; Song IH
Korean J Intern Med; 2020 Nov; 35(6):1305-1316. PubMed ID: 32872729
[TBL] [Abstract][Full Text] [Related]
4. Microbiota issue in CKD: how promising are gut-targeted approaches?
Cosola C; Rocchetti MT; Sabatino A; Fiaccadori E; Di Iorio BR; Gesualdo L
J Nephrol; 2019 Feb; 32(1):27-37. PubMed ID: 30069677
[TBL] [Abstract][Full Text] [Related]
5. Contribution of uremic dysbiosis to insulin resistance and sarcopenia.
Uchiyama K; Wakino S; Irie J; Miyamoto J; Matsui A; Tajima T; Itoh T; Oshima Y; Yoshifuji A; Kimura I; Itoh H
Nephrol Dial Transplant; 2020 Sep; 35(9):1501-1517. PubMed ID: 32535631
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiome in chronic kidney disease: challenges and opportunities.
Nallu A; Sharma S; Ramezani A; Muralidharan J; Raj D
Transl Res; 2017 Jan; 179():24-37. PubMed ID: 27187743
[TBL] [Abstract][Full Text] [Related]
7. Effects of Fecal Microbiota Transplantation on Composition in Mice with CKD.
Barba C; Soulage CO; Caggiano G; Glorieux G; Fouque D; Koppe L
Toxins (Basel); 2020 Nov; 12(12):. PubMed ID: 33255454
[TBL] [Abstract][Full Text] [Related]
8. Gut-Derived Protein-Bound Uremic Toxins.
Graboski AL; Redinbo MR
Toxins (Basel); 2020 Sep; 12(9):. PubMed ID: 32932981
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis.
Rukavina Mikusic NL; Kouyoumdzian NM; Choi MR
Pflugers Arch; 2020 Mar; 472(3):303-320. PubMed ID: 32064574
[TBL] [Abstract][Full Text] [Related]
10. [Pathomechanism and treatment of gut microbiota dysbiosis in chronic kidney disease and interventional effects of Chinese herbal medicine].
Han WB; Liu YL; Wan YG; Sun W; Tu Y; Yang JJ; Wu W; He WM; Yao J
Zhongguo Zhong Yao Za Zhi; 2017 Jul; 42(13):2425-2432. PubMed ID: 28840678
[TBL] [Abstract][Full Text] [Related]
11. Dysbiosis of Gut Microbiota Contributes to Uremic Cardiomyopathy via Induction of IFNγ-Producing CD4
Han B; Zhang X; Wang L; Yuan W
Microbiol Spectr; 2023 Feb; 11(1):e0310122. PubMed ID: 36788674
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiota in chronic kidney disease.
Cigarran Guldris S; González Parra E; Cases Amenós A
Nefrologia; 2017; 37(1):9-19. PubMed ID: 27553986
[TBL] [Abstract][Full Text] [Related]
13. Microbiome in Chronic Kidney Disease (CKD): An Omics Perspective.
Lohia S; Vlahou A; Zoidakis J
Toxins (Basel); 2022 Feb; 14(3):. PubMed ID: 35324673
[TBL] [Abstract][Full Text] [Related]
14. Fecal Microbiota Transplantation in Reducing Uremic Toxins Accumulation in Kidney Disease: Current Understanding and Future Perspectives.
Caggiano G; Stasi A; Franzin R; Fiorentino M; Cimmarusti MT; Deleonardis A; Palieri R; Pontrelli P; Gesualdo L
Toxins (Basel); 2023 Jan; 15(2):. PubMed ID: 36828429
[TBL] [Abstract][Full Text] [Related]
15. Microbiome modulation as a novel therapeutic approach in chronic kidney disease.
Sumida K; Lau WL; Kovesdy CP; Kalantar-Zadeh K; Kalantar-Zadeh K
Curr Opin Nephrol Hypertens; 2021 Jan; 30(1):75-84. PubMed ID: 33148949
[TBL] [Abstract][Full Text] [Related]
16. Gut Microbiome in Chronic Kidney Disease.
Armani RG; Ramezani A; Yasir A; Sharama S; Canziani MEF; Raj DS
Curr Hypertens Rep; 2017 Apr; 19(4):29. PubMed ID: 28343357
[TBL] [Abstract][Full Text] [Related]
17. Microbiota metabolites: Pivotal players of cardiovascular damage in chronic kidney disease.
Cosola C; Rocchetti MT; Cupisti A; Gesualdo L
Pharmacol Res; 2018 Apr; 130():132-142. PubMed ID: 29518493
[TBL] [Abstract][Full Text] [Related]
18. Gut Microbiota-Targeted Interventions in the Management of Chronic Kidney Disease.
Sumida K; Pierre JF; Yuzefpolskaya M; Colombo PC; Demmer RT; Kovesdy CP
Semin Nephrol; 2023 Mar; 43(2):151408. PubMed ID: 37619529
[TBL] [Abstract][Full Text] [Related]
19. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
Felizardo RJF; Watanabe IKM; Dardi P; Rossoni LV; Câmara NOS
Pharmacol Res; 2019 Mar; 141():366-377. PubMed ID: 30639376
[TBL] [Abstract][Full Text] [Related]
20. Dysbiosis-Related Advanced Glycation Endproducts and Trimethylamine N-Oxide in Chronic Kidney Disease.
Taguchi K; Fukami K; Elias BC; Brooks CR
Toxins (Basel); 2021 May; 13(5):. PubMed ID: 34069405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
